Search Results
What do the various non-commercial actors in the antibiotic R&D ecosystem do?
Panel: (Inter)nationalising the antibiotic pipeline: public options for antibiotic R&D
The Crisis in Antibiotic Research and Development
What is the BioP2P Network? Mathias Cousin of Monitor Deloitte
Developing partnerships to bolster the antimicrobial resistance ecosystem: The role of GARDP
Development and access to new antibiotics | EPHA Access to Medicines Forum 2023 #A2M
EPHA #A2MDialogues Sustainable access to effective antibiotics what should the EU do
Conversations with the Academy: Antimicrobial Resistance and the Pharmaceutical Industry
Antimicrobial Resistance 2024 | Keynote by Professor Kevin Outterson
Global Antibiotic R&D Partnership | Mr. Yann Ferrisse | AMR Innovation Dialogue
Press Conference: Launching World's First Antimicrobial Resistance Benchmark a0W0X00000AfRVSUA3
Antibiotic resistance – An approaching crisis?
